19 completed. 19 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow AIDS: new trials by email Literature Review of AIDS trials Research Report on AIDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women Cannabis, Placebo - HIV, AIDS | Phase 2 | Completed | Albert Einstein College of Medicine | 25 | 2020-10-23 | 2025-10-15 |
| Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients single dose of L-AmB, 2 doses of L-AmB, 2 weeks of L-AmB - Histoplasmosis, AIDS | Phase 2 | Completed | Alessandro Pasqualotto | 118 | 2020-02-14 | 2025-03-14 |
| A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF. - AIDS | Phase 2 | Completed | Henan Genuine Biotech Co., Ltd. | 172 | 2017-10-10 | 2019-09-30 |
| A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin - Kaposi's Sarcoma, HIV Positive | Phase 2 | Completed | ImmunityBio, Inc. | 15 | 2014-04-03 | 2024-06-11 |
| Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults Ad35-GRIN, MVA.HIVconsv, pSG2.HIVconsv DNA - AIDS | Phase 1 / Phase 2 | Completed | University of Oxford | 72 | 2014-03-01 | 2016-05-30 |
| Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) DNA vaccine, DNA vaccine prime with the addition of electroporation, rTV boost - AIDS | Phase 2 | Completed | National Center for AIDS/STD Control and Prevention, China CDC | 150 | 2012-08-01 | 2015-05-06 |
| Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations Extended-Release Naltrexone - HIV, AIDS | Phase 1 / Phase 2 | Completed | Yale University | 151 | 2011-03-01 | 2020-03-19 |
| Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons GSK Biologicals HIV Vaccine 732462, Placebo - AIDS | Phase 2 | Completed | GlaxoSmithKline | 191 | 2010-11-08 | 2018-05-21 |
| HIV/AIDS, Severe Mental Illness and Homelessness Skills Building - Motivational Interviewing - HIV, AIDS | Phase 2 | Completed | Boston Medical Center | 240 | 2010-10-01 | 2016-04-01 |
| Study Targeting Affect Regulation Resilient Affective Processing Therapy (RAPT) - HIV, AIDS | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 56 | 2010-09-01 | 2014-10-27 |
| Vitamin D Dose Finding Study Cholecalciferol (Vit D3) - HIV Infections, AIDS | Phase 2 | Completed | Children's Hospital of Philadelphia | 44 | 2010-01-01 | 2013-09-18 |
| Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose GSK Biologicals' HIV vaccine (732461), Chloroquine - AIDS | Phase 2 | Completed | GlaxoSmithKline | 28 | 2009-12-01 | 2018-08-17 |
| Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy dimiracetam, sugar pill - Neuropathy, AIDS | Phase 2 | Completed | Neurotune AG | 116 | 2009-10-01 | 2010-06-02 |
| HIV Prevention for Injecting Drug Users in Kazakhstan Couples Based HIV/STI Risk Reduction Intervention (CHSR), Renaissance Wellness Promotion (WP) - HIV, AIDS | Phase 2 | Completed | Columbia University | 600 | 2008-05-01 | 2014-02-27 |
| Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) Nevirapine based therapy, Efavirenz based therapy, Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) - Tuberculosis, Aids | Phase 2 / Phase 3 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 570 | 2007-12-01 | 2012-02-15 |
| Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers HIV vaccine 732461 - AIDS, HIV Infections | Phase 2 | Completed | GlaxoSmithKline | 180 | 2007-02-20 | 2019-10-01 |
| Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME) Efavirenz (EFV), Lamivudine (3TC), Didanosine (ddI) - HIV Infections, AIDS | Phase 2 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 52 | 2006-02-01 | 2011-12-05 |
| Relaxation Response With Acupuncture for HIV Patients relaxation response - Human Immunodeficiency Virus, AIDS | Phase 2 | Completed | National Center for Complementary and Integrative Health (NCCIH) | 100 | 2003-07-01 | 2006-08-18 |
| L-Carnitine to Treat Fatigue in AIDS Patients L-carnitine, Placebo - HIV Infections, AIDS | Phase 2 | Completed | National Institute of Nursing Research (NINR) | 44 | 2002-11-01 | 2008-09-04 |
Acquired Immunodeficiency Syndrome (19) · HIV Infections (6) · Substance-Related Disorders (2) · Fatigue (1) · HIV Seropositivity (1) · Histoplasmosis (1) · Neoplasms (1) · Neuralgia (1) · Opioid-Related Disorders (1) · Sarcoma (1) · Sarcoma, Kaposi (1) · Systemic carnitine deficiency (1) · Tuberculosis (1) · Wounds and Injuries (1)
Blood-Borne Infections (19) · Communicable Diseases (19) · Genital Diseases (19) · Immune System Diseases (19) · Immunologic Deficiency Syndromes (19) · Infections (19) · Lentivirus Infections (19) · RNA Virus Infections (19) · Retroviridae Infections (19) · Sexually Transmitted Diseases (19) · Sexually Transmitted Diseases, Viral (19) · Slow Virus Diseases (19) · Urogenital Diseases (19) · Virus Diseases (19) · HIV Infections (13)
Carnitine (1) · Chloroquine (1) · Cholecalciferol (1) · Didanosine (1) · Ethambutol (1) · Isoniazid (1) · Lamivudine (1) · Naltrexone (1) · Protons (1) · Pyrazinamide (1) · Rifampin (1) · Sugars (1) · Vaccines, DNA (1) · dimiracetam (1) · efavirenz (1)
GlaxoSmithKline (3) · French National Agency for Research on AIDS and Viral Hepatitis (2) · Albert Einstein College of Medicine (1) · Alessandro Pasqualotto (1) · Boston Medical Center (1) · Children's Hospital of Philadelphia (1) · Columbia University (1) · Henan Genuine Biotech Co., Ltd. (1) · ImmunityBio, Inc. (1) · National Center for AIDS/STD Control and Prevention, China CDC (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · National Institute of Nursing Research (NINR) (1) · Neurotune AG (1) · University of California, San Francisco (1) · University of Oxford (1)
United States (9) · Belgium (2) · China (2) · Brazil (1) · Burkina Faso (1) · France (1) · Germany (1) · Kazakhstan (1) · Kenya (1) · Mozambique (1) · South Africa (1) · Spain (1)
Aboubacar Nacro, MD (1) · Adam Carrico, PhD (1) · Anjali Sharma, MD, MS (1) · Bei-Hung Chang, Sc.D (1) · Daiane Dalla Lana, PhD (1) · Daniel R Malan, MD (1) · Frederick L Altice (1) · Hao Wu, M.D. (1) · Jori Berger-Greenstein, PhD (1) · Maryline Bonnet, MD (1) · Nabila El-Bassel (1) · Nilesh Bhatt, MD (1) · Philippe Msellati, MD, PhD (1) · Ricardo Cruciani, MD, PhD (1)
PMID 24391139, PMID 20516271, PMID 21208909, PMID 21300566, PMID 21857286, PMID 23059649, PMID 23433590, PMID 23719348, PMID 24663014, PMID 24674234, PMID 26560326, PMID 26625449, PMID 29373393, PMID 40342086
K02DA032322 (1), R01AT005531 (1), R21AG059505 (1)